Retatrutide, explained: the triple-hormone drug that isn't approved yet

Retatrutide has substantial weight-loss findings in defined clinical trials but remains investigational. Those results should not be used to rank unrelated products across different trials or validate an online vial. Approved medicines, routine commercial compounding and authorized investigational access follow different requirements.

How retatrutide works: tirzepatide's two signals plus glucagon

Retatrutide hits the same two receptors as tirzepatide, GIP and GLP-1, and adds a third: the glucagon receptor ^[8]. GIP and GLP-1 mostly lower appetite. Glucagon is a hormone that tells the liver to release stored energy.

The thinking behind the third target comes from animal work. In obese mice, the glucagon action raised the calories burned on top of the drop in food intake ^[8]. That paper was written by Lilly scientists. Whether people burn meaningfully more calories is still being studied. For what this means for how you feel, see does retatrutide give you energy.

What the trials show: up to 25% weight loss in 80 weeks

Retatrutide's phase 3 weight losses are large, up to a quarter of body weight on average. They come from Lilly-funded trials of the investigational drug, at doses no regulator has approved.

The cited controlled efficacy trials extend to 80 weeks and do not settle long-term cardiovascular or healthy-aging outcomes. The reviewed TRIUMPH-Outcomes and TRIUMPH-5 registry records are active, not recruiting, with no posted results. They evaluate heart/kidney outcomes and a tirzepatide comparison respectively; registration is not evidence of a completed benefit ^{[3] [2]}. Weight loss also takes some muscle with it; does retatrutide build muscle covers what the one body-scan study measured.

Safety so far: stomach effects, a faster heart rate, more dropouts at higher doses

The trials report the side effects you'd expect from this drug family, plus a few that stand out. There is no FDA-approved prescribing label or approved dose. Investigational oversight is different from marketing approval.

• Stomach. Nausea, diarrhea and vomiting were the most common, rose with dose, and were mostly mild to moderate. A lower starting dose helped in phase 2 ^[9].
• Heart rate. Heart rate went up with dose, peaked around 24 weeks, then eased ^[9].
• Blood pressure and skin sensation. In TRIUMPH-2, low blood pressure and dysesthesia, an odd or painful skin feeling, were more common than on placebo ^[11].
• Dropouts. In TRIUMPH-2, 12% and 8% stopped for side effects or death on the two higher doses, vs 4% on the lowest dose and 5% on placebo. Investigators considered the reported deaths unrelated to the intervention; this does not remove uncertainty about uncommon risks ^[11]. In TRANSCEND-T2D-1 it was 2% to 5%, vs none on placebo ^[14].

FDA status: investigational, not approved, not legal to compound

Retatrutide has no FDA approval for any condition. FDA says it "cannot be used in compounding under federal law," isn't a component of any approved drug, and hasn't been found safe and effective for any condition ^[4].

FDA hasn't announced a decision date, and no approval can be assumed until FDA acts. Check back here: when that changes, this page changes.

The two lawful ways to get retatrutide: a trial or expanded access

Clinical trials and the registered expanded-access program are investigational pathways rather than approved retail treatments. A trial site or treating physician assesses eligibility, and applicable sponsor, regulatory and ethics requirements must be met. A registry listing alone is not authorization for a patient’s treatment ^[1].

1. A clinical trial. Search the current registry for a study and its enrollment status ^[7]. A trial site screens you, gives you the study drug, and follows you closely. Search ClinicalTrials.gov for "retatrutide" and ask your doctor whether one fits.
2. Single-patient expanded access. Lilly lists a pre-approval program, marked "available," that a treating physician requests for one patient ^[6]. It's aimed at adults with severe obesity, meaning a BMI of 35 or more, plus at least two serious or life-threatening obesity-related complications ^[6]. They also need to have not responded to approved treatment, and to be unable to join a trial ^[6].

The expanded-access record also requires discussion of standard options including bariatric surgery. It says availability depends on geography, supply and individual assessment; a status of available does not guarantee access ^[6]. For combining it with other peptides, the answer is covered in can you combine tesamorelin: unapproved commercial combinations should not be confused with an authorized study protocol.

What's sold online as "reta" isn't the trial drug

Websites selling retatrutide "for research use only" are selling unapproved drugs. FDA says these products have been sold straight to consumers with dosing instructions, and urges people not to buy them ^[4].

The problem isn't paperwork. FDA warns that illegally sold GLP-1-type drugs may contain the wrong ingredient, too much or too little of it, or none at all ^[4]. An ordinary telehealth subscription or research-use label does not establish an authorized investigational supply. Ask about the actual protocol and authorization rather than treating a prescription claim as permission for commercial compounding.

If weight or metabolism is your goal today

Approved drugs in related classes have reviewed labels for specific populations and uses. A clinician can discuss whether an approved option fits the medical situation.

• Tirzepatide (Zepbound, Mounjaro) acts on two of retatrutide's three receptors. It produced about 20% weight loss in its main trials.
• Semaglutide acts on GLP-1. Wegovy has a cardiovascular-risk indication in adults with established cardiovascular disease and overweight or obesity; other brands have their own indications.
• Body composition. If keeping muscle is part of the goal, building muscle on tirzepatide covers what's known with an approved drug.

Want to see where approved options fit your goal? The metabolic goal page and the body composition goal page lay them out, or take the quiz.